Lessons learned from the COVID-19 pandemic and its impact on bioanalysis and drug development.
Bioanalysis
; 13(15): 1205-1211, 2021 Aug.
Article
in English
| MEDLINE | ID: covidwho-1317298
ABSTRACT
The COVID-19 pandemic challenged pharmaceutical and bioanalytical communities at large, in the development of vaccines and therapeutics as well as supporting ongoing drug development efforts. Existing processes were challenged to manage loss of staffing at facilities along with added workloads for COVID-19-related study support including conducting preclinical testing, initiating clinical trials, conducting bioanalysis and interactions with regulatory agencies, all in an ultra-rapid timeframes. A key factor of success was creative rethinking of processes and removing barriers - some of which hitherto had been considered immovable. This article describes how bioanalysis was crippled at the onset of the pandemic but how innovative and highly collaborative efforts across teams within and outside of both pharma, bioanalytical labs and regulatory agencies worked together remarkably well.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biological Assay
/
Drug Development
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Bioanalysis
Year:
2021
Document Type:
Article
Affiliation country:
Bio-2021-0120
Similar
MEDLINE
...
LILACS
LIS